Product Description: Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively[1][2].
Applications: Cancer-Kinase/protease
Formula: C18H18Cl3FN4OS
Citations: Patent. US20230147129A1./Cancers (Basel). 2022 May 19;14(10):2493./Cell Syst. 2018 Apr 25;6(4):424-443.e7./Cell. 2024 Feb 1;187(3):624-641.e23./Cold Spring Harb Mol Case Stud. 2022 Jan 10;8(1):a006140./Genes Dis. 2021 Aug 17;9(2):562-575./Int J Cancer. 2020 Apr 1;146(7):1963-1978. /J Biol Chem. 2024 Jan 9:105641./J Cell Biochem. 2024 Jun 11./J Physiol. 2017 Jul 1;595(13):4207-4225./Methods Mol Biol. 2018;1711:351-398./Molecules. 2019 Apr 1;24(7):1260./Research Square Print. October 27th, 2022./Sci Transl Med. 2021 Jan 27;13(578):eaba7308./Theranostics. 2019 Jan 30;9(4):1096-1114.
References: [1]Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659./[2] Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880
CAS Number: 1047645-82-8
Molecular Weight: 463.78
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Akt;PKC;ROCK
English
Deutsch
